文献速递糖尿病

儿童期起病1型糖尿病血糖控制不佳与神经发育障碍风险增加相关:一项基于人群的队列研究

Poor glycaemic control is associated with increased risk of neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study.
PubMed 文献 · Diabetologia · 2021-01-16

该瑞典人群队列研究纳入8430例儿童期起病1型糖尿病患者与84300名匹配对照,随访中位5.6年。1型糖尿病组神经发育障碍诊断率为4.7%,高于对照组的3.6%(校正HR 1.31,95%CI 1.18–1.46)。平均HbA1c>8.6%(>70 mmol/mol)者风险最高(校正HR 1.90,95%CI 1.51–2.37),较HbA1c<7.5%者任何神经发育障碍风险校正HR达3.71(95%CI 2.75–5.02)。

要点

  • 儿童期起病1型糖尿病与神经发育障碍风险增加相关(校正HR 1.31)。
  • HbA1c>8.6%(>70 mmol/mol)者风险最高,较HbA1c<7.5%者校正HR达3.71。
  • 建议对1型糖尿病患儿,尤其血糖控制不佳者,考虑常规神经发育随访。

核心结论

  • 儿童期起病1型糖尿病与后续神经发育障碍风险增加相关,血糖控制不佳者风险最高。
  • 建议在1型糖尿病中考虑常规神经发育随访,尤其对血糖控制不佳的患者。

研究设计与样本

  • 瑞典基于人群的队列研究,使用1973至2013年健康登记数据。
  • 纳入8430例儿童期起病1型糖尿病患者(诊断年龄<18岁,中位起病年龄9.6岁,IQR 5.9–12.9)和84300名按性别、出生年份和出生县匹配的参考个体。
  • 采用Cox模型评估HbA1c对后续神经发育障碍风险的影响。

主要发现

  • 中位随访5.6年,1型糖尿病组398例(4.7%)诊断为任何神经发育障碍,参考组3066例(3.6%),校正HR 1.31(95%CI 1.18–1.46)。
  • 任何神经发育障碍风险随HbA1c水平升高而增加,平均HbA1c>8.6%(>70 mmol/mol)者风险最高(校正HR 1.90,95%CI 1.51–2.37)。
  • 与HbA1c<7.5%(<58 mmol/mol)的糖尿病患者相比,HbA1c>8.6%(>70 mmol/mol)者任何神经发育障碍风险校正HR 3.71(95%CI 2.75–5.02)。
  • 特定神经发育障碍风险:ADHD校正HR 4.16(95%CI 2.92–5.94),ASD校正HR 2.84(95%CI 1.52–5.28),智力障碍校正HR 3.93(95%CI 1.38–11.22)。

临床怎么用

  • 对儿童期起病1型糖尿病患者,尤其血糖控制不佳者,应考虑常规神经发育随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to investigate the effect of childhood-onset type 1 diabetes on the risk of subsequent neurodevelopmental disorders, and the role of glycaemic control in this association. We hypothesised that individuals with poor glycaemic control may be at a higher risk of neurodevelopmental disorders compared with the general population, as well as compared with individuals with type 1 diabetes with adequate glycaemic control. METHODS: This Swedish population-based cohort study was conducted using data from health registers from 1973 to 2013. We identified 8430 patients with childhood-onset type 1 diabetes (diagnosed before age 18 years) with a median age of diabetes onset of 9.6 (IQR 5.9-12.9) and 84,300 reference individuals from the general population, matched for sex, birth year and birth county. Cox models were used to estimate the effect of HbA1c on the risk of subsequent neurodevelopmental disorders, including attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorders (ASD) and intellectual disability. RESULTS: During a median follow-up period of 5.6 years, 398 (4.7%) individuals with type 1 diabetes received a diagnosis of any neurodevelopmental disorder compared with 3066 (3.6%) in the general population, corresponding to an adjusted HR (HRadjusted) of 1.31 (95% CI 1.18, 1.46) after additionally adjusting for other psychiatric morbidity prior to inclusion, parental psychiatric morbidity and parental highest education level. The risk of any neurodevelopmental disorder increased with HbA1c levels and the highest risk was observed in patients with mean HbA1c >8.6% (>70 mmol/mol) (HRadjusted 1.90 [95% CI 1.51, 2.37]) compared with reference individuals without type 1 diabetes. In addition, when compared with patients with diabetes with HbA1c <7.5% (<58 mmol/mol), patients with HbA1c >8.6% (>70 mmol/mol) had the highest risk of any neurodevelopmental disorder (HRadjusted 3.71 [95% CI 2.75, 5.02]) and of specific neurodevelopmental disorders including ADHD (HRadjusted 4.16 [95% CI 2.92, 5.94]), ASD (HRadjusted 2.84 [95% CI 1.52, 5.28]) and intellectual disability (HRadjusted 3.93 [95% CI 1.38, 11.22]). CONCLUSIONS/INTERPRETATION: Childhood-onset type 1 diabetes is associated with an increased risk of neurodevelopmental disorders, with the highest risk seen in individuals with poor glycaemic control. Routine neurodevelopmental follow-up visits should be considered in type 1 diabetes, especially in patients with poor glycaemic control.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Liu S, Kuja-Halkola R, Larsson H, et al. Poor glycaemic control is associated with increased risk of neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study. Diabetologia. 2021. PMID: 33454829. doi:10.1007/s00125-020-05372-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。